Hypophosphatasia: Clinical Trials

12 trials for Hypophosphatasia, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

10 completed, 1 recruiting, 1 withdrawn. 12 Phase 2, 3 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 212Completed 10, Recruiting 1, Withdrawn 1
Phase 13Completed 2, Recruiting 1
Phase 31Completed 1

Follow Hypophosphatasia: new trials by email Literature Review of Hypophosphatasia trials Research Report on Hypophosphatasia

Trials (filtered) newest first · largest first

All 12 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALE1 in Healthy Adults and Adults With Hypophosphatasia in Order to Identify Suitable Doses of ALE1
ALE1, Placebo - Hypophosphatasia (HPP)
Phase 1 / Phase 2RecruitingAlesta Therapeutics1202025-09-302026-08-03
Pilot Trial of Single Dose Ilofotase Alfa in Hypophosphatasia
Ilofotase Alfa, 0.8 mg/kg, Ilofotase Alfa, 3.2 mg/kg - Hypophosphatasia
Phase 1 / Phase 2CompletedAM-Pharma122023-05-152025-02-27
Pharmacokinetic and Dose Response Study of Asfotase Alfa in Adult Patients With Pediatric-Onset Hypophosphatasia (HPP)
Asfotase alfa - Hypophosphatasia
Phase 2CompletedAlexion Pharmaceuticals, Inc.272016-06-062019-09-17
Safety and Efficacy of Asfotase Alfa in Patients With Hypophosphatasia (HPP)
Asfotase Alfa (ALXN1215) - Hypophosphatasia
Phase 2CompletedTranslational Research Center for Medical Innovation, Kobe, Hyogo, Japan132014-08-012016-03-31
Dose Escalation Study to Evaluate the Safety and Tolerability of Multiple Infusions of BPS804 in Adults With Hypophosphatasia (HPP)
BPS804 - Hypophosphatasia
Phase 2CompletedUltragenyx Pharmaceutical Inc82011-07-012022-09-16
Open-Label Study of Asfotase Alfa in Infants and Children ≤ 5 Years of Age With Hypophosphatasia (HPP)
asfotase alfa - Hypophosphatasia
Phase 2 / Phase 3CompletedAlexion Pharmaceuticals, Inc.692010-07-012019-03-13
Safety and Efficacy Study of Asfotase Alfa in Adolescents and Adults With Hypophosphatasia (HPP)
asfotase alfa - Hypophosphatasia
Phase 2CompletedAlexion Pharmaceuticals, Inc.192010-06-012019-03-13
Extension Study of Protocol ENB-006-09 - Study of Asfotase Alfa in Children With Hypophosphatasia (HPP)
Asfotase Alfa - Hypophosphatasia (HPP)
Phase 2CompletedAlexion Pharmaceuticals, Inc.122010-04-012019-03-13
Safety and Efficacy of Asfotase Alfa in Juvenile Patients With Hypophosphatasia (HPP)
asfotase alfa - Hypophosphatasia (HPP)
Phase 2CompletedAlexion Pharmaceuticals, Inc.132009-09-012019-04-01
Safety and Efficacy Study of ENB-0040 in Juvenile Patients With Hypophosphatasia (HPP)
ENB-0040 - Hypophosphatasia
Phase 2WithdrawnAlexion Pharmaceuticals, Inc.2009-07-012023-08-04
Extension Study of Protocol ENB-002-08 - Study of Asfotase Alfa in Infants and Young Children With Hypophosphatasia (HPP)
asfotase alfa - Hypophosphatasia
Phase 2CompletedAlexion Pharmaceuticals, Inc.102009-04-012019-03-13
Safety and Efficacy Study of Asfotase Alfa in Severely Affected Infants With Hypophosphatasia (HPP)
asfotase alfa - Hypophosphatasia (HPP)
Phase 1 / Phase 2CompletedAlexion Pharmaceuticals, Inc.112008-09-012019-04-01

Narrower conditions

Osteomalacia (7)  ·  Rickets (7)  ·  Bone Diseases (6)

Broader conditions

Congenital, Hereditary, and Neonatal Diseases and Abnormalities (12)  ·  Genetic Diseases, Inborn (12)  ·  Metabolic Diseases (12)  ·  Metabolism, Inborn Errors (12)  ·  Metal Metabolism, Inborn Errors (12)  ·  Nutritional and Metabolic Diseases (12)  ·  Avitaminosis (7)  ·  Bone Diseases, Metabolic (7)  ·  Calcium Metabolism Disorders (7)  ·  Deficiency Diseases (7)  ·  Malnutrition (7)  ·  Musculoskeletal Diseases (7)  ·  Nutrition Disorders (7)  ·  Vitamin D Deficiency (7)  ·  Bone Diseases (1)

Interventions

asfotase alfa (9)  ·  setrusumab (1)

Sponsors

Alexion Pharmaceuticals, Inc. (8)  ·  AM-Pharma (1)  ·  Alesta Therapeutics (1)  ·  Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan (1)  ·  Ultragenyx Pharmaceutical Inc (1)

Countries

United States (7)  ·  Canada (5)  ·  Germany (5)  ·  United Kingdom (4)  ·  Japan (2)  ·  United Arab Emirates (2)  ·  Australia (1)  ·  France (1)  ·  Italy (1)  ·  New Zealand (1)  ·  Russia (1)  ·  Saudi Arabia (1)  ·  Spain (1)  ·  Turkey (Türkiye) (1)

Top investigators

Keiichi Ozono (1)  ·  Michael P. Whyte, MD (1)

Results publications

PMID 26529632, PMID 32417537, PMID 32762706, PMID 27699270, PMID 22397652, PMID 28436937, PMID 30558909, PMID 30811537, PMID 30969260, PMID 32987199, PMID 33822385, PMID 41378916